Morales BJE

Language: Spanish
References: 25
Page: 10-16
PDF size: 63.21 Kb.

ABSTRACT

Pulmonary hypertension is a prevalent disease with multiple etiologies. Some decades ago, the knowledge about pulmonary hypertension (PTH) was scant whereas this disease has bad a poor prognosis and few therapeutic alternatives.
At the beginning, the contributions its understanding were isolated, but the PTH epidemic aroused the concern of the clinics in Europe and there was the first meeting was held in 1973 for the PHT. Them, it was suggested a classification, from a morphologic point of view. At the same time, take care of looking for a this profile of primary pulmonary arterial hypertension (PPH), which definition, some years later, would be defined by USA National Institutes.
It is until 1998, in Evian, France, when a clinical classification is established, and used up to now. That classification share both histopathological features and similar physiopathogenesis, as well as clinical. All of them are a great support for clinical diagnosis and treatment about the different forms of PHT.
One of the principal aspects of this classification are the new treatments and another in experimental phase. The main objective of this research is to find drugs with less contralateral effects, easy to handle and of lesser cost. The first studies were carried out in PPH, but actually they apply to some other forms of PTH.

REFERENCES

1. Fishman AP. A Century of Primary Pulmonary Hypertension. In: Rubin LJ, Rich S, editors. Primary Pulmonary Hypertension. New York: Marcel Dekker, 1997:1-17.

2. Cournand A, Ranges HA. Catheterization of Right Auricle in Man. Proc Soc Exp Biol Med 1941;46:462.

3. Dresdale DT, Schultz M, Michtom RJ. Primary Pulmonary Hypertension. Am J Med 1951;11:686-705.

4. Heath D, Edwards JE. The pathology of Hypertensive Pulmonary Vascular Disease. A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Deffects. Circulation 1958;18:533-547.

5. Kay JM, Smith P, Heath D. Aminorex and the Pulmonary Circulation. Thorax 1971;26:262-270.

6. Hantano S, Strasser T. Primary Pulmonary Hypertension. Report of the WHO Meeting. Geneva: World Health Organization, 1975.

7. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary Pulmonary Hypertension. A National Prospective Study. Ann Intern Med 1987;107:216-223.

8. Rich S, editor. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998 co-esponsored by the World Health Organization. Disponible en: HTTP:/www.woo.int/ncd/cvd/pph.html

9. Loyd JE, Slovis B, Phillips JA III, Butler MG , Foroud TM, Conneally PM, et al. The Presence of Genetic Anticipation Suggests that the Molecular Basis of Familial Primary Pulmonary Hypertension may be a Trinucleotide Repeat Expansion. Chest 1997;111:82S-83S.

10. 10.Baldesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension due to the Scleroderma Spectrum of Disease. A Randomized, Controlled Trial. Ann Intern Med 2000; 132:425-434.

11. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. Short-term and Long-term Epoprostenol (Prostacyclin) Therapy in Pulmonary Hypertension Secondary to Conective Tissue Diseases: Results of a Pilot Study. Eur Respir J 1999;13:1351-1356.

12. Herve P, Lebrel D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary Vascular Disorders in Portal Hypertension. Eur Respir J 1998; 11:1153-66-64.

13. 13.Taurá P, García-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, et al. Moderate Primary Pulmonary Hypertension in Patients Undergoing Liver Transplantation. Anesth Analg 1996;83:675-680.

14. Ribas J, Angrill J, Barberà JA, García-Pagán JC, Roca J, Bosch J, Rodríguez-Roisin R. Isosorbide-5-mononitrate in the Treatment of Pulmonary Hypertension Associated with Portal Hypertension. Eur Respir J 1999;13:210-212.

15. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous Intravenous Infusion of Epoprostenol for the Treatment of Portopulmonary Hypertension. Transplantation 1997;63:604-606.

16. Brickner M, Hillis L, Lange R. Congenital Heart Disease in Adults. First of two parts. New England J Med 2000;342:256-263.

17. Pellicelli A, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related Pulmonary Hypertension. Ann NY Acad Sci 2001;946:82-94.

18. Stricker H, Domenighetti G. Prostacyclin for HIV Associated Pulmonary Hypertension. Ann Intern Med 1997;127:1043.

19. Abenhaim L, Moride Y, Brenot F. Rich S, Benichou J, Kurz X, et al. Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-616.

20. Mandel J, Mark EJ, Hales CA. Pulmonary Veno-occlusive Disease. Am J Respir Crit Care Med 2000;162:1964-1973.

21. Barberá JA. Chronic Obstructive Pulmonary Disease. In: Roca J, Rodríguez-Roisin R, Wagner PD, editors. Pulmonary and Peripheral Gas Exchange in Health and Disease. New York: Marcel Dekker, 2000:229-261.

22. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-Term Oxygen Therapy can Reverse the Progression of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Am Rev Respir Dis 1985;131:493-498.

23. Fedullo PF, Auger WR, Kerr KM. Rubin LJ. Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2001;345:1465-1472.

24. Mc Laughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: a Case Series. Ann Intern Med 1999; 130:740-743.

25. Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D. High-Resolution CT of the Chest in four Patients with Pulmonary Capillary Hemangiomatosis or Pulmonary Venoocclusive Disease. Am J Roentgenol 1998;171:1321-1324.